By Daniel DeNoon
Reviewed By Charlotte Grayson
For every milestone in cancer research, there are countless men and women to thank. Through their creativity and dogged determination, people have hope in preventing, living with, even curing some forms of cancer.
Here are just a few of the milestones in the war on cancer, and some of the researchers who made them:
Researcher finds that the male hormone testosterone and the female hormone estrogen drive the growth of prostate and breast cancers, respectively. Research receives the Nobel Prize in Physiology or Medicine in 1966. Learn more about the causes of prostate and breast cancer.
Scientist discovers growth factors; substances that can help tumors grow. Research wins Nobel Prize in Physiology or Medicine in 1986.
American Cancer Society advocates widespread use of the Pap smear. This simple test results in more than a 70% decrease in deaths from cervical and uterine cancers.
Judah Folkman, MD, of Harvard University discovers that tumors create a network of blood vessels to bring them oxygen so they can grow. He calls this process angiogenesis.
Henry Lynch, MD, describes the first hereditary cancer family syndrome.
Surgeon General announces that cigarette smoking is definitely linked to cancer.
The first cancer-causing gene, or oncogene, is discovered.
Also during the '70s:
A handful of forward-thinking surgeons say that simple mastectomy -- removal of only the breast itself -- is just as effective as a radical mastectomy.
Among those visionary breast cancer researchers: Bernard Fisher, MD, director of the National Surgical Adjuvant Breast and Bowel Project, and Umberto Veronesi, MD, researcher with the European Institute of Oncology in Milan, Italy. Both launched long-term studies of these techniques.
Learn more about recent breast cancer research milestones.
President Richard Nixon declares a national war on cancer. The National Cancer Act is signed by President Nixon, establishing a national program to search for a cancer cure.
Scientist pioneers the technique of bone marrow transplantation to treat cancer. Researchers receive the Nobel Prize in Physiology or Medicine in 1990.
Paul Berg, PhD, clones the first gene. He receives Nobel Prize in Chemistry in 1980.
Researchers develop technology that leads to the development of a monoclonal antibody that can enhance the immune system. This research leads to the development of several promising cancer drugs in the late 1990s and early 2000s. The researchers receive the Nobel Prize in Physiology or Medicine in 1984.
Learn more about monoclonal antibodies and other cutting-edge cancer treatments.
Researchers develop procedures to sequence DNA, which allows scientists to study the actions of specific genes. This research receives the Nobel Prize in Chemistry in 1980.
Tamoxifen is approved by the FDA for treating estrogen receptor-positive breast cancer.
Researchers develop and carry out the first trial of tamoxifen to prevent recurrence in breast cancer survivors.
Researcher finds the first cancer-causing gene - an oncogene -- in human bladder cancer. More than 50 oncogenes are known today.
Scientist discovers the p53 protein, later found to be the most frequently mutated gene in human cancer.
Researchers discover the first virus that causes cancer, HTLV-1, which causes T-cell leukemia in humans.
Early detection guidelines are set for breast cancer.
Scientists develop the prostate-specific antigen (PSA) test for screening and early detection of prostate cancer.
Researcher develops the first "transgenic mouse," a mouse with a gene for rat growth hormone, opening up new ways to research how cancers are caused and treated.
Scientist discovers the role of dendritic cells, which later become the basis for vaccines to treat cancer.
Judah Folkman's team finds the first angiogenic factor, paving the way for new drug development.
Researcher clones the first of some 20 now-known genes that can suppress tumors, the retinoblastoma gene of a childhood eye cancer.
A compound called taxol, derived from the bark of the pacific yew tree, is hailed as the most promising new cancer drug in decades. It quickly becomes the standard therapy for ovarian cancer and is also used in treating lung and breast cancers.
Dennis Slamon, MD, discovers that the HER2/neu receptor is overexpressed in 15% to 30% of breast cancers and is an unfavorable prognostic feature.
The race is on to discover more angiogenic factors to suppress the growth of tumors. A team of scientists discover VEGF in 1989. Folkman discovers angiostatin and endostatin in 1991.
The Cancer Prevention Trial II shows a lower risk of colon cancer among people who eat diets rich in fruits and vegetables. Data from the Cancer Prevention Trial II also show a lower risk in people who take aspirin regularly.
Cancer-causing agents in the environment -- such as radiation from the sun and chemicals from cigarette smoke -- became more closely linked to specific gene damage that can cause cancers.
The rate of smoking drops from 45% of the population in 1946 to 25% of people.
Exercise found to reduce risk of breast cancer in premenopausal women.
The second breast cancer gene (BRCA2) is discovered.
Irinotecan is approved for treating advanced colon cancer.
Scientist reports that selenium reduces the risk of lung, colon, and prostate cancer.
First overall decrease in cancer deaths is documented. Cancer deaths fell 0.5% per year between 1990 and 1995.
Researchers clone the gene for telomerase, an enzyme believed to be specific for cancer cells.
Judah Folkman, MD, and Timothy Browder, MD, cure cancer in mice by blocking the blood supply of tumors with angiostatin and endostatin (anti-angiogenesis). Testing of the anti-angiogenesis drug Avastin begins in people.
FDA approves monoclonal antibody therapy (Rituxan) for B-cell lymphoma. By 1998, the overall five-year survival rates for the disease are improved to 58%.
New cases of cancer decline. Overall cancer incidence rates fell 0.7% per year between 1990 and 1995.
Scientist reports that tamoxifen reduces the incidence of breast cancer by 45% in high-risk women, the first successful study of treatments to prevent breast cancer.
Dennis Slamon, MD, PhD, shows that a genetically engineered monoclonal antibody called Herceptin improves survival of women with advanced breast cancer. FDA grants approval of the novel drug to treat advanced breast cancer.
Scientists turn a normal human cell into a cancer cell with three defined elements: an oncogene, inactivation of two suppressor genes, and the gene for telomerase.
Cancer incidence and mortality rates continue to decline.
Brian Druker, MD, begins phase II trial of STI-571 (Gleevec), a drug that inhibits an enzyme present only in chronic myelogenous leukemia (9CML) cells, after it caused remission in all 31 CML patients of his phase I study.
The draft sequence of the human genome is announced.
A team of scientists announce that the combination of chemotherapy with p53 gene therapy caused tumors to shrink in 25% to 30% of head and neck cancer patients.
Researchers report that an experimental monoclonal antibody, IMC-C225 (will become Erbitux), is effective in the treatment of refractory colon and head and neck cancers.
After three years of study, arsenic (Trisenox) is approved as an orphan drug for treatment of patients with acute promyelocytic leukemia (APL). Orphan drugs treat rare medical conditions; manufacturers receive financial incentives to develop such drugs.
The Cox-2 inhibitor Celebrex is approved by the FDA for the prevention of colon cancer polyps in individuals carrying a specific gene that causes familial adenomatous polyposis, a form of colon cancer. In April 2005, the FDA asked that Celebrex carry new warnings about the potential risk of heart attacks and strokes as well as potential stomach ulcer bleeding risks. Clinical trials for prevention of sporadic colon cancer and other cancers are ongoing.
Researchers report that the first human clinical trials of endostatin (an anti-angiogenesis drug) show that it is safe and may have anticancer potential.
FDA approves Gleevec (formerly STI 571) for treatment of chronic myelogenous leukemia.
Researchers report that IMC-C225 plus the drug Camptosar produced a response in colorectal cancers resistant to standard treatment in phase II trials. IMC-C225, later renamed Erbitux, is a monoclonal antibody that slows cancer growth by targeting a protein found on the surface of some cells called the epidermal growth factor receptor (EGFR). EGFR plays a role in regulating cell growth.
Judah Folkman, MD, predicts cancer will be "treatable" within the next decade.
DNA microarray technology (gene chip) is successful in predicting which node-negative breast cancer patients will go on to develop metastasis and thus benefit from aggressive adjuvant therapy.
Researchers announce a new screening test for colon cancer that detects specific genetic abnormalities in stool samples of up to 70% of patients with colon cancer.
Studies show the potential superiority of two new hormone therapies for breast cancer, Arimidex and Femara.
Study shows that Avastin improves survival for people with advanced colon cancer.
Learn about these two major cancer advancements.
Researchers find that a simple blood test helps predict colon cancer.
FDA approves Erbitux to treat colon cancer.
Avastin becomes the first anti-angiogenesis drug approved by the FDA for the treatment of colorectal cancer. Other anti-angiogenesis drugs are in the pipeline for approval.
Originally published Feb. 26, 2004.
Medically updated April 12, 2005.
SOURCES: National Cancer Institute. The National Foundation for Cancer Research. The American Cancer Society. Johns Hopkins University. WebMD Feature: "Cutting-Edge Breast Cancer Therapy."
©1996-2005 WebMD Inc. All rights reserved.